Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endocyte Inc (NASDAQ:ECYT)

During the Trading Day
5.28 +0.09 / +1.73%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
5.28 0.00 / 0.00%
Volume: 250.00
Health Technology

Company Description

Endocyte, Inc. is a biopharmaceutical company, which develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.

Contact Information

Endocyte, Inc.
3000 Kent Avenue
West Lafayette Indiana 47906
P:(765) 463-7175
Investor Relations:



Individual stakeholders22.33%
Mutual fund holders21.63%
Other institutional18.26%

Top Executives

P. Ron EllisPresident, Chief Executive Officer & Director
Michael A. ShermanChief Operating & Financial Officer
Philip S. LowDirector & Chief Science Officer
Christopher P. LeamonVice President-Research & Development
Scot L. HarperVice President-Clinical Operations